v3.26.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Gamma Delta T cell (Details)
1 Months Ended 6 Months Ended 12 Months Ended
Mar. 02, 2026
USD ($)
Dec. 11, 2025
USD ($)
Apr. 08, 2025
USD ($)
Dec. 27, 2024
agreement
Dec. 31, 2024
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
HeXun                
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                
Total consideration $ 474,000 $ 825,000            
Research and development expenses           $ 825,000    
Remaining consideration           260,700    
Amount paid under agreement           213,300    
New product pipeline                
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                
Research and development expenses           1,168,071 $ 699,771  
Related Party                
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                
Research and development expenses             448,571  
Related Party | JY BioMed                
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                
License period     20 years          
Notice period for termination of agreement     30 days          
Threshold period for correction of material breach     30 days          
Initial consideration paid         $ 1,000,000 1,000,000    
Total consideration     $ 38,000,000          
Research and development expenses           0 $ 448,571  
Remaining consideration           $ 37,000,000    
Related Party | JY BioMed | Pancreatic cancer products                
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                
Percentage of royalty     7.00%          
Related Party | JY BioMed | Brain cancer products                
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                
Percentage of royalty     10.00%          
CTO | JY BioMed                
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES                
Number of license agreement | agreement       2        
Ownership interest (as a percent)           76.00%   76.00%